

Supplemental Table S1. Exclusion Criteria Regarding Prior Use of Osteoporosis Treatment

Treatment	Exclusion criteria
Oral bisphosphonates	Any dose received within 3 months prior to randomization More than 1 month of cumulative use between 3 and 12 months prior to randomization More than 3 years of cumulative use, unless last dose received ≥ 5 years prior to randomization
Intravenous bisphosphonates	Zoledronic acid: Any dose received within 3 years prior to randomization More than one dose received within 5 years prior to randomization Ibandronate, pamidronate, or alendronate: Any dose received within 12 months prior to randomization More than 3 years of cumulative use, unless last dose received ≥ 5 years prior to randomization
Teriparatide or any parathyroid hormone analogues	Any dose received within 3 months prior to randomization More than 1 month of cumulative use between 3 and 12 months prior to randomization
Strontium ranelate or fluoride (for osteoporosis)	More than 1 month of cumulative use within 5 years prior to randomization
Denosumab or any cathepsin K inhibitor, such as odanacatib	Any dose received within 18 months prior to randomization
Tibolone, cinacalcet, or calcitonin	Any dose received within 3 months prior to randomization
Systemic oral or transdermal estrogen or selective estrogen receptor modulators	More than 1 month of cumulative use within 6 months prior to randomization
Activated vitamin D3, vitamin K2	More than 1 month of cumulative use within 6 months prior to randomization
Hormonal ablation therapy	More than 1 month of cumulative use within 6 months prior to randomization